Guerrero A, Cobo J, Fortún J, Navas E, Quereda C, Asensio A, Cañón J, Blazquez J, Gómez-Mampaso E
Infectious Disease and Clinical Microbiology Department, Hospital Ramón y Cajal, Universidad de Alcalá de Henares, Madrid, Spain.
Lancet. 1997 Dec 13;350(9093):1738-42. doi: 10.1016/S0140-6736(97)07567-3.
Since 1990, several nosocomial outbreaks of multidrug-resistant (MDR) tuberculosis have occurred, none of which have involved Mycobacterium bovis. We describe an epidemic of nosocomial and primary MDR M bovis tuberculosis from December, 1993, to February, 1995, among HIV-1-infected patients in a district of Madrid.
We undertook genetic characterisation of the M bovis strain and investigated its presence in a tuberculosis epidemic in a Madrid hospital in a case-controlled study. We assessed 19 cases diagnosed with MDR tuberculosis due to M bovis during the study period. For the control group, we randomly selected 33 patients with HIV-1 infection and isolation of a strain of M tuberculosis susceptible to isoniazid, rifampicin, or both, who were treated in Ramón y Cajal Hospital. Infection-control policies and practices were implemented.
We detected 19 cases in HIV-1-infected patients of primary MDR tuberculosis produced by M bovis resistant to 11 antituberculosis drugs. We found phenotypic and genotypic similarities in the strains of M bovis. In the case group, the index case and two other cases had had previous contact with another hospital that had had an MDR tuberculosis outbreak. All patients died after a mean of 44 days (range 2-116), despite multidrug treatment with first-line and second-line antituberculosis drugs. The cases with M bovis MDR tuberculosis were significantly more likely than controls to have been admitted to a hospital ward at the same time as patients already infected with MDR tuberculosis during the 10 months before their diagnosis (adjusted odds ratio 94.6 [95% CI 9.4-956.3], p < 0.0001). Advanced HIV-1 immunosuppression was associated with the development of MDR tuberculosis. Implementation of control measures stopped the epidemic.
An M bovis primary MDR tuberculosis epidemic that cannot be treated effectively and with high mortality has emerged in Europe and has been transmitted between hospitals.
自1990年以来,已发生数起耐多药(MDR)结核病的医院内暴发,其中均未涉及牛分枝杆菌。我们描述了1993年12月至1995年2月间,在马德里一个区的HIV-1感染患者中发生的医院内和原发性耐多药牛分枝杆菌结核病疫情。
我们对牛分枝杆菌菌株进行了基因特征分析,并在一项病例对照研究中调查了其在马德里一家医院结核病疫情中的存在情况。我们评估了研究期间诊断为牛分枝杆菌所致耐多药结核病的19例病例。对于对照组,我们随机选择了33例在拉蒙·伊·卡哈尔医院接受治疗的HIV-1感染患者,他们分离出的结核分枝杆菌菌株对异烟肼、利福平或两者敏感。实施了感染控制政策和措施。
我们在HIV-1感染患者中检测到19例原发性耐多药结核病病例,由对11种抗结核药物耐药的牛分枝杆菌引起。我们发现牛分枝杆菌菌株在表型和基因型上具有相似性。在病例组中,首例病例和另外两例病例曾与另一家发生过耐多药结核病暴发的医院有过接触。尽管使用一线和二线抗结核药物进行了多药治疗,但所有患者在平均44天(范围2 - 116天)后均死亡。在诊断前10个月内,与已感染耐多药结核病的患者同时入住医院病房的情况下,牛分枝杆菌耐多药结核病病例比对照组更有可能出现(调整后的优势比为94.6 [95%可信区间9.4 - 956.3],p < 0.0001)。晚期HIV-1免疫抑制与耐多药结核病的发生有关。控制措施的实施阻止了疫情的蔓延。
欧洲出现了一种无法有效治疗且死亡率高的牛分枝杆菌原发性耐多药结核病疫情,并已在医院之间传播。